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Summary
Drug resistance remains a major obstacle to successful cancer treatment. A database of drug-associated gene expression
profiles was screened for molecules whose profile overlapped with a gene expression signature of glucocorticoid (GC)
sensitivity/resistance in acute lymphoblastic leukemia (ALL) cells. The screen indicated that the mTOR inhibitor rapamycin
profile matched the signature of GC sensitivity. We tested the hypothesis that rapamycin would induce GC sensitivity in
lymphoid malignancy cells and found that it sensitized to GC-induced apoptosis via modulation of antiapoptotic MCL1.
These data indicate that MCL1 is an important regulator of GC-induced apoptosis and that the combination of rapamycin
and glucocorticoids has potential utility in lymphoid malignancies. Furthermore, this approach represents a strategy for
identification of promising combination therapies for cancer.Introduction
Multiple studies have demonstrated the potential for gene ex-
pression profiling to identify cancers that will recur after treat-
ment with multiagent chemotherapy (Buckhaults, 2006; Heuser
et al., 2005; Mintz et al., 2005; van’t Veer et al., 2002). The
overarching goal for such an approach to cancer therapy is
that patients with the highest risk of relapse might be identified
and treated with a different, more effective therapy. Unfortu-
nately, in most cases, amore effective alternative does not exist.
Therefore, we have focused on how signatures associated with
poor prognosis might be used to direct therapeutic approaches
in addition to identifying patients with poor prognosis. As re-
lapses are likely to be at least partially a result of intrinsic cellular
resistance to the chemotherapeutic agents being used, gene
expression signatures associated with relapse might be used
to identify approaches to reverse drug resistance. But, givenCANCER CELL 10, 331–342, OCTOBER 2006 ª2006 ELSEVIER INC. DOthat most patients are treated with multiple agents that likely
have different mechanisms of resistance, and in vivo response
to therapy is influenced by multiple factors that may not be in-
trinsic to the cancer cell, it is not immediately obvious how to
use such gene expression data to guide therapeutic strategies.
While we have previously used gene expression analysis to
identify the receptor tyrosine FLT3 as a potential therapeutic tar-
get in specific subsets of childhood acute lymphoblastic leuke-
mia due to its differential expression, this approach requires sig-
nificant prior knowledge about the associated biology in order to
make such associations (Armstrong et al., 2003). Therefore, new
approaches are needed if gene expression analysis is to guide
the identification of therapeutic approaches.
One striking example in which resistance to a cancer therapeu-
tic predicts outcome is resistance to glucocorticoid treatment in
childhood acute lymphoblastic leukemia (ALL). Resistance to
glucocorticoid-induced apoptosis of primary lymphoblasticS I G N I F I C A N C E
Multiple studies have demonstrated that gene expression profiling can be used to identify patients with differing prognoses. However, it
has been more difficult to use this information to develop therapeutic approaches. Here we show that disease-associated signatures
can be computationally connected to drug-associated profiles in order to identify molecules that reverse a drug resistance signature.
Demonstration that rapamycin reverses glucocorticoid resistance via MCL1 modulation prompts investigation of this combination in
lymphoblastic leukemia and suggests that such a gene expression-based chemical genomic approach might be usedmore broadly
to identify molecules (drugs) that reverse gene expression signatures associated with poor prognosis and drug resistance.I 10.1016/j.ccr.2006.09.006 331
A R T I C L Eleukemia cells in vitro predicts a poor prognosis in childhood
ALL (Hongo et al., 1997; Kaspers et al., 1997, 1998; Pieters
et al., 1991). In vivo response to 7 days of monotherapy with
prednisone is also a strong and independent prognostic factor
in childhood ALL (Dordelmann et al., 1999; Kaspers et al.,
1998). The importance of glucocorticoid resistance in ALL is fur-
ther highlighted by the fact that it remains a strong predictor of
a poor prognosis even when assessed in a subset of ALL cases
harboring the t(9;22), cases traditionally considered to have one
of the worst outcomes in ALL. Since glucocorticoids (GC) are
critical to many biologic processes and are a cornerstone of
ALL therapy, there have been many studies of GC and the GC
receptor (GR) mechanism of action and resistance that have ex-
plored multiple avenues (Tissing et al., 2003). However, the pre-
cise explanation for sensitivity versus resistance toGC in ALL re-
mains largely unknown.
Alterations of critical control points in the intrinsic apoptotic
pathway are an attractive potential mechanism to explain GC
sensitivity and resistance. Defective apoptosis is a hallmark of
cancer (Hanahan and Weinberg, 2000), and the ability to acti-
vate the apoptotic program is an important determinant of effi-
cacy for anticancer drugs (Fesik, 2005; Reed, 1995). Members
of the BCL2 protein family play critical roles in the intrinsic apo-
ptotic program controlling whether an apoptotic signal will result
in cell death (Danial and Korsmeyer, 2004). In response to vari-
ous apoptotic stimuli, proapoptotic BH3-only members induce
activation of BAX and BAK, and cytochrome c release from
mitochondria, thus triggering activation of caspases through
the apoptosome complex (Danial and Korsmeyer, 2004). Con-
versely, antiapoptotic members such BCL2, BCL-XL, or MCL1
antagonize BH3-only proteins, thereby inhibiting BAX and BAK
activation and apoptosis (Danial and Korsmeyer, 2004). The
proapoptotic molecules BIM and PUMA are necessary for ap-
propriate GC-induced apoptosis, and BIM expression is rapidly
induced after GC treatment of ALL cells (Abrams et al., 2004;
Erlacher et al., 2005; Wang et al., 2003). Overexpression of anti-
apoptotic BCL2 protects CCRF-CEM lymphoblastic leukemia
cells from GC-induced apoptosis (Hartmann et al., 1999). More-
over, Bax2/2;Bak2/2 double knockout (DKO) lymphocytes that
have a complete block in the intrinsic apoptotic pathway are
resistant to GC (Lindsten et al., 2000; Takeuchi et al., 2005).
Finally, high-level expression of the antiapoptotic MCL1 is cor-
related with in vitro GC resistance (Holleman et al., 2004).
Given that in vitro GC resistance can be accurately assessed
in ALL samples, and this resistance is predictive of a poor out-
come, we asked whether we could combine a GC sensitivity/
resistance gene expression signature with a database of gene
expression data derived from a diversity of bioactive small mol-
ecules to identify compounds that could modulate this biology.
Using this approach, we identified rapamycin as a potential GC
resistance reversal agent, and MCL1 as an important modulator
of GC-induced apoptosis.
Results
The Connectivity Map identifies rapamycin as a potential
GC resistance reversal agent
In order to identify a gene expression signature associated with
GC resistance, we performed gene expression analysis on pre-
treatment ALL samples that were determined to be either332sensitive (IC50 < 150 mg/ml prednisolone) or resistant (IC50 >
150 mg/ml prednisolone) to GC-induced apoptosis in vitro
(Den Boer et al., 2003; Pieters et al., 1991). RNA was isolated
from 13 sensitive and 16 resistant diagnostic ALL samples and
hybridized to Affymetrix U133A microarrays. One hundred and
fifty-seven probe sets were significantly correlated with the sen-
sitive/resistant distinction after correction for multiple hypothe-
sis testing (p < 0.0005) (Figure 1A) (Figure S1 in the Supplemen-
tal Data available with this article online). Comparison of our
signature with a previously defined signature for GC sensitiv-
ity/resistance demonstrated overlap of the resistance signature
including increased expression of antiapoptotic MCL1 in resis-
tant cells (Figure S1) (Holleman et al., 2004).
Having defined a signature of GC resistance, we sought to
develop a strategy to reverse the signature, and by inference, re-
verse the resistance phenotype. We hypothesized that a com-
pendium of gene expression profiles representing pharmaco-
logic treatment of cells might be used to identify compounds
that modulate the GC resistance signature. To test this hypoth-
esis, we made use of a database of 453 genome-wide expres-
sion profiles derived from the treatment of a variety of human
cell lines with 164 bioactive small molecules, the majority of
which are established pharmaceuticals or compounds with
known activities, referred to as the Connectivity Map (Table
S1) (Lamb et al., 2006). We used a gene set enrichment metric
based on the Kolmogorov-Smirnov statistic (Lamb et al., 2003)
to rank order these 453 individual treatment instances by their
similarity to the resistance/sensitive signature. Remarkably,
the ten instances of the mammalian target of rapamycin
(mTOR) inhibitor sirolimus (more commonly known as rapamy-
cin) were ranked near the top of the Connectivity Map list, an
observation far beyond that expected by chance (p < 1025)
(Figure 1C). This analysis indicated that rapamycin is positively
connected with the sensitive versus resistance signature and
suggested the hypothesis that this small molecule could induce
GC sensitivity in glucocorticoid-resistant ALL cells. Rapamycin
inhibits the activity of mTOR, which is activated by PI3K/Akt
pathway (Hay and Sonenberg, 2004). Also consistent with the
connection of the GC resistance signature to this pathway
was the observation that the GC resistance signature was highly
enriched in genes associated with the AKT pathway. Specifi-
cally, gene set enrichment analysis (GSEA) (Subramanian
et al., 2005) using 163 gene sets derived from the BioCarta path-
way database (Majumder et al., 2004), indicated that nine gene
sets were significantly enriched in the resistant samples as de-
termined by permutation testing (p < 0.005) (Figure 1B). The
AKT pathway was themost highly enriched gene set in the resis-
tant samples, further suggesting a potential role for the PI3K/
AKT/mTOR pathway in GC resistance. The enrichment of AKT
pathway-associated genes in GC-resistant samples and the
Connectivity Map-based identification of rapamycin as a poten-
tial GC resistance reversal agent focused our attention on the
PI3K/AKT/mTOR pathway and prompted further assessment
of rapamycin.
Rapamycin reverses the glucocorticoid resistance
signature in lymphoid cells
In order to further verify the overlap between a rapamycin profile
and our GC resistance signature, we assessed overlap between
the genes highly expressed in resistant ALL samples and genes
that decreased after rapamycin treatment in independentCANCER CELL OCTOBER 2006
A R T I C L EFigure 1. Gene expression-based screening identifies rapamycin as a potential sensitizing agent to GC-induced apoptosis
A: The top 50 probe sets that are correlated with either GC sensitivity or resistance are shown. A detailed list of genes can be found at http://www.broad.mit.
edu/cgi-bin/cancer/datasets.cgi/. Permutation analysis identified 157 probes correlated with this distinction (p < 0.0005).
B: GSEA analysis was performed using 163 pathway-associated gene sets curated by Biocarta to assess for enrichment of specific pathways in either resistant
or sensitive samples. All pathways that demonstrated enrichment with p < 0.005 are demonstrated and ordered based on the p value. Note that all gene sets
with enrichment were more highly expressed in the resistant ALL samples.
C: Sirolimus (rapamycin) is positively connected with the GC resistance/sensitivity signature. The ‘‘barview’’ is constructed from 453 horizontal lines, each
representing an individual treatment instance in the Connectivity Map data set, ordered by their corresponding connectivity score with the query signature.
Each of the ten rapamycin instances in the data set is colored in black. Colors applied to the remaining instances reflect the sign of their scores (green,
positive; gray, null; red, negative).
D: CEM-c1 cells were treated with either DMSO or 10 nM rapamycin for 3 and 24 hr after which the gene expression profile was determined. The 157 probe sets
used in 1C were assessed for overlap with those genes more highly expressed in the cells treated with DMSO (resistant) as compared to those treated with
rapamycin (potentially sensitive). The blue lines demonstrate where the GC probe sets fall within the 22,000 probe sets ordered from left (1) to right
(22,000) based on the DMSO/rapamycin distinction with gene #1 most highly expressed in DMSO-treated cells. The red line represents the running ES score
that becomes more positive as probe sets are identified toward the top of the list before they would be expected if randomly distributed. Note that at
24 hr more probe sets (blue lines) are identified toward the top (left) of the ordered list of genes.experiments. First, we treated the GC-resistant T cell lympho-
blastic leukemia cell line CEM-c1 with rapamycin and deter-
mined the gene expression profile 3 and 24 hr after rapamycin
treatment. Using the genes highly expressed in resistant ALL
samples as a gene set, we performed GSEA against the CEM-
c1 cell lines that were treated with rapamycin or DMSO for 3
or 24 hr. This analysis demonstrated a progressive overlap be-
tween those genes whose expression decreased after rapamy-
cin treatment and genes highly expressed in GC-resistant sam-
ples (Figure 1D). We also used GSEA to demonstrate partial
reversal of the GC resistance signature in a previously pub-
lished profile obtained after rapamycin treatment of humanCANCER CELL OCTOBER 2006B-lymphoma cells (data not shown) (Majumder et al., 2004;
Peng et al., 2002). Given the consistent gene expression con-
nection between GC sensitivity/resistance and rapamycin treat-
ment, we performed further studies to assess the efficacy and
mechanism of rapamycin reversal of GC resistance.
Rapamycin sensitizes lymphoid malignancy cells to GC
As mTOR is downstream of AKT in some cell types (Gingras
et al., 2001; Hay and Sonenberg, 2004), we tested if activated
AKT induced GC resistance, and if this resistance could be re-
versed by rapamycin. We transduced the GC-sensitive mouse
T-hybridoma 2B4 cell line (Memon et al., 1995) with a retrovirus333
A R T I C L Eencoding GFP and a constitutively active form of Akt (Myr-Akt).
The 2B4 cells expressing Myr-Akt were more resistant to GC-
induced apoptosis than either the uninfected parental 2B4 cells
(data not shown) or the control virus-transduced 2B4 cells
(Figure 2A), indicating that activation of the Akt pathway can
confer GC resistance. Next, we determined to what extent the
GC resistance induced byMyr-Akt was due to mTOR activation.
We treated 2B4 cells expressing Myr-Akt with rapamycin and
then tested their GC sensitivity. Treatment with 10 nM rapamy-
cin reversed a portion of the GC resistance induced byMyr-AKT
returning the GC sensitivity back to that of wild-type 2B4 cells
(Figure 2A). When control 2B4 cells were incubated with 10 nM
rapamycin,wenoted a further sensitization toGC-induceddeath
(Figure 2A). Furthermore, all of the GC-induced death could
be reversed by the GC receptor antagonist RU486 (data not
shown), thus demonstrating the specificity of the GC effect.
These data indicate that AKT activation can induce GC resis-
tance and that a portion of the resistance works via an mTOR-
dependent pathway.
The fact that rapamycin could sensitize 2B4 cells to GC led us
to investigate this effect on a panel of human cell lines derived
from patients with lymphoid malignancies. First, we demon-
strated inhibition of ribosomal S6 phosphorylation by 10 nM
rapamycin, thus confirming effective inhibition of mTOR at this
concentration (Figure S2A). Multiple cell lines, including a T-
ALL cell line (CEM-c1), a B-ALL cell line (697), and multiple
Burkitt’s lymphoma cell lines (Raji, NAMALWA, Ramos), demon-
strated enhanced apoptosis when rapamycin and glucocorti-
coids were used in combination (Figure 2B). Of note, some
human lymphoid leukemia cell lines (such as REH) were not sen-
sitized, likely due to a different mechanism of GC resistance
in these lines (Figure 2B). We confirmed that rapamycin alone,
at concentrations up to 100 nM, did not induce apoptosis
in CEM-c1 (Figure 2C), 697, Ramos, or NAMALWA cell lines
(Figure S3). However, after pretreatment with 10 nM rapamycin,
the CEM-c1 (Figure 2D), 697 (Figure 2E), Ramos (Figure 2F), and
NAMALWA (Figure S2C) cells demonstrated a shift in the IC50
for dexamethasone. To test whether rapamycin treatment sim-
ply reduced the apoptotic threshold, we tested other drugs on
rapamycin-pretreated CEM-c1 cells. Neither staurosporine-,
vincristine-, doxorubicin-, nor etoposide-induced apoptosis
was influenced by rapamycin pretreatment (Figure S4). There-
fore, rapamycin sensitizes lymphoid malignancy cells to GC-
induced apoptosis via a mechanism that does not enhance
sensitivity to all drugs.
Rapamycin downregulates antiapoptotic MCL1
in lymphoid malignancy cells
BCL2 family members are critical regulators of the intrinsic apo-
ptotic pathway and play critical roles in GC-induced apoptosis.
Therefore, we determined which members of the BCL2 family
might regulate GC-induced apoptotic events in these cells.
BIM andPUMAareBH3-onlymembers of the BCL2 protein fam-
ily induced by GC in lymphoid cells and are required for GC-in-
duced apoptosis (Erlacher et al., 2005; Villunger et al., 2003).
BIM expression is also induced by glucocorticoids in ALL cells
(Abrams et al., 2004; Schmidt et al., 2006). We measured BIM
and PUMA levels and confirmed BIM induction in CEM-c1 cells
(Figures 3A and 3B) and 697 cells (data not shown). However, we
found that rapamycin did not affect the level of BIM transcripts
or protein (Figures 3A and 3B). Even though PUMA is induced334by dexamethasone in some lymphoid cells (Erlacher et al.,
2005), it was not induced in CEM/c1, 697, or 2B4 cells
(Figure 3A and data not shown). Furthermore, rapamycin did
not affect the level of PUMA transcripts when cells were treated
Figure 2. Rapamycin sensitizes lymphoid malignancy cells to GC-induced
apoptosis
A: Mouse T cell hybridoma 2B4 cells were engineered to express a constitu-
tively active form of Akt by retroviral transduction. The GFP-positive Akt-
transduced or control-transduced cells were treated with an increasing
concentration of dexamethasone for 14 hr with or without 10 nM rapamy-
cin, followed by FACS analysis. GFP-positive cells were assessed for viability
by Annexin V staining.
B: A panel of lymphoid malignancy-derived cell lines were treated with ve-
hicle control, 10 nM rapamycin, 1 mM dexamethasone, or the combination
of dexamethasone and rapamycin, and the percentage of viable cells was
determined at 48 hr.
C: Viable cells were assessed in T-ALL CEM-c1 cells after treatment with
increasing concentrations of rapamycin at 24, 48, and 72 hr.
D: The percentage of viable cells was determined in CEM-c1 cells 24 hr after
treatment with an increasing concentration of dexamethasone6 pretreat-
ment with 10 nM rapamycin.
E: The percentage of viable cells was determined in 697 cells 24 hr after
treatment with an increasing concentration of dexamethasone 6 10 nM
rapamycin.
F: The percentage of viable cells was determined in Ramos cells 48 hr after
treatment with an increasing concentration of dexamethasone 6 10 nM
rapamycin.
Error bars represent the mean 6 standard deviation.CANCER CELL OCTOBER 2006
A R T I C L EFigure 3. Rapamycin specifically downregulates
MCL1 among BCL2 family proteins
A: Dexamethasone-induced expression of BH3-
only Bim and Puma was not affected by rapa-
mycin in CEM-c1 cells as determined by quanti-
tative real-time PCR analysis. Error bars represent
the mean 6 standard deviation of triplicates.
B: CEM-c1 cells were pretreated with or without
Rapamycin for 16 hr, followed by 1 mM dexa-
methasone for the indicated time, and Bim ex-
pression was assessed by immunoblot.
C: CEM-c1 cells were treated with rapamycin at
the indicated concentration for 16 hr, and antia-
poptotic protein expression was assessed by
immunoblot.
D–F: 697 cells (D), NAMALWA cells (E), or Ramos
cells (F) were treated with rapamycin for 16 hr,
and MCL1 levels were assessed by Western blot-
ting. All cell lines demonstrated > 90% viability
when they were assessed for MCL1 expression.
G: MCL1 expression was assessed in 2B4 cells ex-
pressing constitutively active Akt as compared
to vector control.in the presence or absence of dexamethasone (Figure 3A).
Therefore, it appears that modulation of BIM and PUMA expres-
sion is not the mechanism by which rapamycin sensitizes cells
to GC-induced apoptosis.
Next,weassessed the levels of antiapoptotic BCL2 family pro-
teins in CEM-c1 cells treated with rapamycin. The level of BCL2
and BCL-XL did not change, but MCL1, an antiapoptotic protein
essential for lymphoid cell survival (Opferman et al., 2003), was
reduced (Figure 3C). A similar decrease inMCL1expression after
rapamycin treatment was demonstrated in 697 (Figure 3D),
NAMALWA (Figure 3E), andRamos (Figure 3F) cells. Conversely,
MCL1 levels were higher in the GC-resistant 2B4 cells express-
ing Myr-Akt as compared to control GC-sensitive 2B4 cells
(Figure 3G), similar to previous reports demonstrating modula-
tion of MCL1 levels by AKT activation (Liu et al., 2001; Wang
et al., 1999). Therefore, activation of AKT may confer GC resis-
tance through augmentation ofMCL1 levels, while at least a por-
tion of the rapamycin-mediated sensitization of lymphoid malig-
nancy cells may work via a decrease in MCL1 expression.
Overexpression of MCL1 sequesters BIM and renders
cells resistant to GC
Given that MCL1 expression is correlated with GC resistance
in ALL (Figure 1) (Holleman et al., 2004), Mcl1 is a criticalCANCER CELL OCTOBER 2006antiapoptotic factor in murine lymphocyte development and
survival (Opferman et al., 2003), and rapamycin modulates
MCL1 levels (Figure 3), we hypothesized that MCL1 may be a
critical regulator of GC-induced apoptosis and part of themech-
anism by which rapamycin sensitizes cells to glucocorticoids.
2B4 cells transduced with a retrovirus encoding MCL1 ex-
pressed 4- to 8-fold higher levels than cells infected with a con-
trol virus (Figure 4A). After 16 hr of dexamethasone exposure,
only 30% of 2B4 cells transduced with a control virus were via-
ble, whereas over 90% of cells overexpressing MCL1 were via-
ble (Figure 4B). As expected, MCL1 overexpression inhibited
apoptosis via a number of different stimuli (Figure S5). However,
the greatest protection was conferred against GC-induced apo-
ptosis (Figure 4B) (Figure S5). MCL1 expression similarly pro-
tected GC-sensitive human 697 cells from GC-induced apopto-
sis (Figure S6). Next, we expressed a FLAG-tagged MCL1
whose level was not regulated by rapamycin (Figure S7A) and
found that 2B4 cells expressing the FLAG-tagged MCL1 were
protected against GC-induced apoptosis even if treated with
rapamycin and dexamethasone (Figure 4C).
Next, we wanted to further investigate the mechanism of
MCL1-mediated protection against GC-induced death. We hy-
pothesized the BH3-only protein BIM induced by GC-treatment
(Figure 3) might be sequestered by MCL1 and thus unable to335
A R T I C L EFigure 4. Expression of MCL1 confers GC resistance and sequesters BIM
2B4 cells overexpressing MCL1 are resistant to dexamethasone treatment.
A: MCL1 overexpression in 2B4 cells by retroviral-mediated expression.
B: 2B4 cells transduced with either an MCL1 retrovirus or vector control were treated with increasing concentrations of dexamethasone for 16 hr, followed by
FACS analysis for Annexin V staining.
C: 2B4 cells expressing FLAG-MCL1 or control were treated with increasing concentrations of dexamethasone and either 0 nM (0R), 1 nM (1R), or 10 nM (10R)
rapamycin for 16 hr, followed by FACS analysis.
D: 2B4 cells expressing FLAG-MCL1 were treated with 100 nM dexamethasone for the indicated time, and immunoprecipitation with an anti-FLAG M2 antibody
was performed. Immunoprecipitated BIM and MCL1 were assessed by immunoblot.
E: Bim expression was suppressed by lentivirus-mediated shRNA. Extra-long (EL), long (L), and short (S) isoforms of BIM were assessed by immunoblot.
F: 2B4 cells transduced with the Bim-directed shRNA or a control luciferase-directed shRNA were treated with dexamethasone for 16 hr, followed by FACS
analysis. Luc, control luciferase knockdown. BimKD, BIM knockdown.
Error bars represent the mean 6 standard deviation.activate proapoptotic BAX/BAK as a mechanism of resistance.
To test this hypothesis, 2B4 cells expressing FLAG-MCL1
were treated with 100 nM dexamethasone for 0, 4, 8, and 24
hr, then subjected to immunoprecipitation using an anti-FLAG
antibody. We found progressive accumulation of a BIM/MCL1
complex during the course of the experiment (Figure 4D). Even
after BIM expression is induced by dexamethasone, themajority
of BIM is bound by MCL1 (Figure 4D and Figure S7B), indicating
MCL1 is amajor antiapoptotic protein sequestering BIM in these
cells. To test the extent to which BIM plays a role in GC sensitiv-
ity in this cell line, we knocked down Bim expression in 2B4 cells
by lentivirus-mediated short-hairpin RNA (shRNA) expression
(Figure 4E). Bim knockdown cells are more resistant to dexa-
methasone than 2B4 cells transduced with a control lentivirus
(Figure 4F), indicating that BIM is a key BH3-only protein in
this context. Recently, it has been shown that decreased BIM
expression renders 697 cells resistant to GC (Abrams et al.,
2004). Our data are consistent with this report and the data
from murine models demonstrating an important role for BIM
in GC-induced apoptosis (Bouillet et al., 1999; Erlacher et al.,
2005). We note that Bim knockdown 2B4 cells are less resistant336to GC than 2B4 cells overexpressing MCL1, presumably be-
cause MCL1 inhibits other proapoptotic proteins important for
GC-induced apoptosis. Therefore, overexpression of MCL1
confers GC resistance in 2B4 cells and works at least in part
by sequestration of proapoptotic Bim. Furthermore, MCL1 ap-
pears to be a key player in rapamycin-mediated sensitization
to GC-induced apoptosis.
Overexpression of MCL1 renders primary lymphocytes
resistant to GC-induced apoptosis
To further demonstrate the role of MCL1 in GC resistance, we
assessed transgenic mice that express murine Mcl1 under the
control of the major histocompatibility complex class I gene
(H2Kb) promoter (Figure 5A) (J.T.O., unpublished data). The
H2K promoter is well characterized and has been reported to
drive high-level expression in all hematopoietic lineages (Domen
et al., 2000). Furthermore, in this model, the cDNA for Mcl1 has
had its 30-UTR and polyA replaced with that of the Moloney
MuLV enhancer/polyA to facilitate message stabilization. West-
ern blot analysis revealed approximately 2- to 3-fold elevated
levels of MCL1 in the thymocytes or splenocytes of oneCANCER CELL OCTOBER 2006
A R T I C L EH2K-Mcl1 transgenic line (Figures 5B and 5C). Analysis of
splenic B cell and thymic T cell development in this line showed
no gross differences in lymphocyte development (J.T.O., un-
published data). In order to examine the contribution of Mcl1
to GC resistance in primary lymphoid cells, thymocytes and
splenic B220+ B cells were treated with dexamethasone ex
vivo. Both B and T lymphoid cells from mice with the H2K-
Mcl1 transgene showed GC resistance as compared to cells
from control littermates (Figures 5D and 5E). After 24 hr dexa-
methasone treatment, fewer than 10% of thymocytes from con-
trol littermates were viable (Annexin V/propidium iodide [PI] dou-
ble-negative) at a concentration of 100 nM dexamethasone,
whereas over 40% of thymocytes from H2K-Mcl1 transgenic
mice were viable (Figure 5D). Similarly, splenic B cells with the
H2K-Mcl1 transgenewere relatively resistant toGC-induced ap-
optosis (Figure 5E). Therefore, overexpression of MCL1 induces
GC resistance in primary lymphoid cells.
MCL1 suppression sensitizes cells to GC-induced
apoptosis
Several antiapoptotic BCL2 family proteins have been shown to
confer GC resistance in ALL cell lines and thymocytes from
transgenic mice when overexpressed (Chao et al., 1995; Grillot
et al., 1995; Memon et al., 1995; Sentman et al., 1991; Siegel
et al., 1992; Strasser et al., 1991). For example, like MCL1,
Figure 5. MCL1 confers GC resistance in primary lymphoid cells
A: Illustration of H2K-Mcl1 transgene construct.
B: An immunoblot for MCL1 expression in thymocytes from H2K-Mcl1 trans-
genic and wild-type mice.
C: Immunoblot for MCL1 expression in splenocytes from H2K-Mcl1 transgenic
and wild-type mice.
D: Thymocytes from H2K-Mcl1 transgenic mice and littermate controls were
treated with increasing concentrations of dexamethasone for 24 hr fol-
lowed by FACS analysis for Annexin V2/PI2 thymocytes.
E: B220+, Annexin V2/PI2 splenic B cells were counted as viable cells and
standardized against cells without dexamethasone treatment. Four mice
for each genotype were tested. Representative results are shown.
Error bars represent the mean 6 standard deviation.CANCER CELL OCTOBER 2006BCL2 or BCL-XL renders 2B4 cells resistant to GC (Memon
et al., 1995). However, only MCL1, but not BCL2 or BCL-XL, is
overexpressed in GC-resistant ALL cells from primary patients
(Figure 1) (Holleman et al., 2004). Furthermore, while rapamycin
sensitizes cells to GC, only MCL1, but not BCL2 or BCL-XL, is
downregulated in rapamycin-treated cells. Therefore, we hy-
pothesized thatMCL1 is a key antiapoptotic BCL2 family protein
responsible for GC resistance. To test this hypothesis,MCL1 ex-
pression was suppressed by an MCL1-directed shRNA (Fig-
ure 6A) in the CEM-c1, 697, and NAMALWA cell lines. All lines
transducedwith theMCL1 shRNAdemonstrated increased sen-
sitivity to GC treatment (Figures 6B, 6E, and 6F). Furthermore,
similar to cells treated with rapamycin, the cells treated with
the MCL1-directed shRNA were sensitized to GC to a greater
extent than any other drug tested (Figures 6C and 6D) (Fig-
ure S8). In contrast, when BCL2 expression was suppressed
with high efficiency in CEM-c1 cells (Figure 6G), the cells were
still resistant to GC-induced apoptosis (Figure 6H). Therefore,
it appears that MCL1 is the key antiapoptotic protein governing
GC resistance in these cells.
Discussion
We have used an approach to drug discovery based on in silico
screening for compounds that reverse a gene expression signa-
ture to identify the mTOR inhibitor rapamycin as a potential
reversal agent for GC resistance. Given that rapamycin is an
FDA-approved drug known to be safe when coadministered
with glucocorticoids, andGSEA analysis identified AKT pathway
members as highly expressed in resistant samples, we decided
to further investigate the potential role for rapamycin as a GC re-
sistance reversal agent in lymphoid malignancy cells. In order to
activate the mTOR pathway, we expressed a constitutively ac-
tive AKT (Myr-Akt) in a cell line previously demonstrated to be
sensitive to GC-induced apoptosis. Pretreatment with rapamy-
cin reversed a significant portion of the AKT-mediated GC resis-
tance, demonstrating that mTOR activation can play a role in GC
resistance. Furthermore, rapamycin treatment sensitized both
GC-resistant and -sensitive human lymphoid malignancy cell
lines to GC-induced apoptosis. In order to determine if rapamy-
cin affected the intrinsic apoptotic pathway as a mechanism
for reversal of GC resistance, we assessed levels of pro- and
antiapoptotic BCL2 family member proteins after rapamycin
treatment. Rapamycin specifically reduced the expression of
MCL1 but did not affect the level of BCL2 and BCL-XL, or the
induction of BIM by dexamethasone. Similar to rapamycin treat-
ment, reduction ofMCL1 levels by RNAi sensitized cells to dexa-
methasone-induced apoptosis, whereas RNAi-mediated reduc-
tion of BCL2 had no effect on GC resistance in CEM-c1 cells.
These data show the utility of in silico drug screening and
prompt further characterization of the role of MCL1 and its
inhibition by rapamycin in GC resistance.
Rapamycin and glucocorticoid treatment in ALL
Rapamycin and other mTOR inhibitors are currently in early-
phase clinical trials for a number of malignancies based on the
importance of the AKT/mTOR pathway in cancer biology. In
some tumors where PTEN, a negative regulator of PI3K/AKT/
mTOR pathway, is inactivated, cells exhibit enhanced sensitivity
to the rapamycin analog CCI-779 (Guertin and Sabatini, 2005).
Furthermore, multiple studies have demonstrated synergy337
A R T I C L EFigure 6. MCL1, but not BCL2, is required for GC resistance in lymphoid
malignancy cells
A:MCL1 expression was assessed in CEM-c1 cells transduced with a lentivirus
expressing either a luciferase-directed shRNA or an MCL1-directed shRNA,
or after treatment with either 10 nM rapamycin or DMSO.
B: CEM-c1 cells treated with either shRNA or rapamycin/DMSO as in A were
treated with increasing concentrations of dexamethasone. Note that the
CEM-c1 cells transduced with the MCL1 shRNA and the rapamycin-treated
CEM-c1 cells are equally sensitive to dexamethasone.
C: CEM-c1 cells treated with either control or MCL1-directed shRNAs
were treated with increasing concentrations of doxorubicin.
D: CEM-c1 cells treated with either control or MCL1-directed shRNAs
were treated with increasing concentrations of etoposide.
E: 697 cells treated with either control or MCL1-directed shRNAs
were treated with increasing concentrations of dexamethasone.
F: NAMALWA cells treated with either control or MCL1-directed shRNAs
were treated with increasing concentrations of dexamethasone.
G: BCL2 suppression in CEM-c1 cells transduced with a BCL2-directed
shRNA.338between mTOR inhibition and chemotherapy, heightening inter-
est in this approach (Kasukabe et al., 2005; Marimpietri et al.,
2005; Mondesire et al., 2004; Wendel et al., 2004). However, it
has been difficult to determine where introduction of an mTOR
inhibitor might have its greatest clinical impact, perhaps due
to the lack of a mechanistic understanding of the observed syn-
ergistic effects with chemotherapy, and the fact that it remains
unclear to what extent resistance to any particular chemothera-
peutic agent is important for outcome in most cancers. As resis-
tance to GC-induced apoptosis is widely recognized as a deter-
minant of poor prognosis in ALL, and based on data presented
here, we can now assess inhibition of MCL1 expression as a
mechanism for increased sensitivity to glucocorticoids in pa-
tients with GC-resistant ALL. Furthermore, as rapamycin is an
FDA-approved drug, and glucocorticoids have been safely
given in combination to patients post-solid organ transplants,
clinical development of such an approach can proceed rapidly.
Preliminary studies demonstrate rapamycin sensitization to GC-
induced apoptosis in a subset of primary ALL samples. A de-
tailed characterization of such responses is required and will
be the focus of future studies. A previous study demonstrated
lack of BIM activation as another potential mechanism of GC re-
sistance in ALL (Bachmann et al., 2005), providing support for
the idea that the intrinsic apoptotic pathway is critical for GC-in-
duced apoptosis. However, cells unable to activate BIM expres-
sion in response to GC might be predicted to be resistant to the
GC/rapamycin combination; thus, further study will focus on the
identification of samples/patients likely to respond to this drug
combination.
An interesting issue is the mechanism by which rapamycin
leads to decreased MCL1 and sensitizes to GC-induced apo-
ptosis. Given the broad effects of rapamycin on cellular metab-
olism, pathways in addition to MCL1 may also contribute. How-
ever, as rapamycin and the MCL1 shRNA lead to similar
decreases in MCL1 expression and GC sensitization, MCL1 ap-
pears to be an important component of rapamycin-mediated
sensitization in these studies. MCL1 levels decrease by >50%
in rapamycin-treated cells that are sensitized to glucocorticoids.
Previous studies using Mcl1 knockout mice have shown that
Mcl1+/2 hematopoietic cells are sensitized to some death stimuli
(J.T.O., unpublished data). Thus, modest decreases in MCL1
level appear to have a significant effect on the apoptotic thresh-
old to certain stimuli. It is likely that a portion of the rapamycin-
mediated MCL1 regulation is via inhibition of mRNA translation.
Given that the MCL1 protein is highly regulated and rapidly de-
graded (Maurer et al., 2006; Nijhawan et al., 2003), inhibition of
translation would lead to a rapid decrease in protein level.
Whether there is a direct of effect of rapamycin onMCL1 protein
degradation is an important area for future investigation.
Specificity of anti- and proapoptotic proteins in cancer
drug resistance
Glucocorticoids induce apoptosis via activation of the intrinsic
apoptotic program, as demonstrated by resistance to GC-
induced apoptosis in BAX/BAK null lymphocytes (Lindsten
et al., 2000; Takeuchi et al., 2005). Furthermore, proapoptotic
H: CEM-c1 cells with decreased BCL2 expression are still resistant to dexa-
methasone-induced apoptosis. Cells were subjected to increasing concen-
trations of dexamethasone for 24 hr followed by FACS analysis.
Error bars represent the mean 6 standard deviation.CANCER CELL OCTOBER 2006
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optosis in murine lymphoid cells (Bouillet et al., 1999; Villunger
et al., 2003). The demonstration that high-level MCL1 expres-
sion is correlated with GC resistance suggests it may play a
role in GC resistance (Figure 1) (Holleman et al., 2004). Previous
studies demonstrate the importance of Mcl1 in hematopoietic
cell survival (Opferman et al., 2003, 2005; Zhou et al., 1998).
Our demonstration that overexpression of MCL1 inhibits GC-
induced apoptosis and shRNA-mediated inhibition of MCL1 ex-
pression sensitizes cells to GC-induced apoptosis provides
functional validation of the role of MCL1 in GC-induced apopto-
sis. It is of interest to note that inhibition of BCL2 expression had
no effect on the sensitivity to GC-induced apoptosis in CEM-c1
cells. These data are in keepingwith growing evidence that there
is functional heterogeneity of the antiapoptotic BCL2 family
members (Chen et al., 2005; Kuwana et al., 2005). This has sig-
nificant implications for the development of combination thera-
pies thatmight take advantage of small molecules directed to in-
hibit specific BCL2 family members. For example, potent,
specific small molecule inhibitors of BCL2 have recently been
reported (Oltersdorf et al., 2005). Our data suggest that such
molecules might not be uniformly effective at reversing GC
resistance unless they also inhibited MCL1 function. In fact,
ABT-737 does not sensitize 2B4 cells expressingMCL1 to dexa-
methasone-induced apoptosis (Certo et al., 2006). Further char-
acterization of whichmembers of the BCL2 family are involved in
the regulation of apoptosis induced by specific therapeutics will
help guide more rational, and hopefully more effective, clinical
trials.
Gene expression-based drug screening as a tool
for drug discovery
An ever-increasing number of gene expression-based genomic
analyses are being performed to develop refined signatures of
cancer that may be useful for identification of subsets of disease
that respond differently to current therapies. However, convert-
ing the data contained in these signatures into therapeutic ap-
proaches remains difficult. The simplest approach uses the
gene expression data to identify a therapeutic target (e.g., a ki-
nase) that is highly expressed in a given tumor (Armstrong et al.,
2003). While we have previously used this approach, it requires
significant prior knowledge of the importance of the gene of in-
terest or a commitment to fully characterize multiple individual
gene products with no guarantee that any will be of relevance.
Therefore, we set out to determine if we could identify therapeu-
tic approaches via computational connection of a disease state
such as GC resistance to gene expression profiles identified by
treatment of cancer cell lines with small molecules. The identifi-
cation of rapamycin as a GC resistance reversal agent via in sil-
ico drug screening provides evidence that such an approach
may provide a tool for the development of combination thera-
pies for cancer.
The ability to use gene expression profiles of particular dis-
ease states as a tool for drug screening promises to significantly
enhance the drug discovery process. We have previously used
gene expression profiles as markers for specific cellular pheno-
types in high-throughput small molecule screens. This ap-
proach, called gene expression-based high-throughput screen-
ing, or GE-HTS (Stegmaier et al., 2004), allows one to screen
libraries of small molecules for those that reverse (or activate)
a signature of interest. The approach described here, theCANCER CELL OCTOBER 2006Connectivity Map, is an approach that allows rapid in silico as-
sessment of molecules contained in the database and their abil-
ity to reverse signatures associated with specific disease states
or drug resistance profiles. Thus, we envision the Connectivity
Map as a tool to rapidly assess for potential activity of the thou-
sands of small molecules in the database, and GE-HTS as
a complementary approach that is amenable to screening
many different libraries of small molecules for a specific activity.
Further incorporation of genomic approaches should increase
the efficiency of the drug discovery and development process.
Experimental procedures
Microarray analysis of GC-sensitive and GC-resistant ALL samples
Diagnostic bonemarrow specimens were characterized as sensitive or resis-
tant to GC-induced apoptosis as previously described (Den Boer et al., 2003;
Pieters et al., 1991). Gene expression data were normalized using dChip (Li
and Wong, 2001) and filtered with a max-min = 100 and max/min = 4. The
probe sets correlated with the sensitive/resistant distinction were deter-
mined using a signal-to-noise statistic and permutation testing. The 157
probe sets with p < 0.0005 were determined to be part of a GC sensitivity/
resistance profile and used for subsequent comparisons. Pediatric ALL sam-
ples were obtained either from the German Cooperative ALL (COALL) group
or the ErasmusMC, Sophia Children’s Hospital. Approval was obtained from
the Erasmus MC Institutional Review Board for these studies. Informed
consent was obtained according to the Declaration of Helsinki.
Connectivity Map
The current version of the Connectivity Map data set (build01) contains ge-
nome-wide expression data for 453 treatment and vehicle control pairs, rep-
resenting 164 distinct small molecules. A complete description of the data
set is provided as Table S1. Enrichment of both the up- and downregulated
genes from a given signature in the profiles of each treatment instance were
estimated with a metric based on the Kolmogorov-Smirnov statistic, as de-
scribed (Lamb et al., 2006) and combined to produce a ‘‘connectivity score.’’
Connectivity score was set to zero (‘‘null’’) where the enrichment scores for
the up- and downregulated gene sets were of the same sign. Instances
were rank ordered in descending order of connectivity score. We used the
Kolmogorov-Smirnov statistic to estimate the significance of the concentra-
tion of rapamycin instances when ranked by the connectivity score. For
100,000 trials, ten instances were selected at random from the set of 453,
and the number of times the statistic for the set of rapamycin instances
was equaled or exceeded was recorded. The frequency of this event can
be taken as a p value and was found to be zero. All data for the connectivity
map can be found at http://www.broad.mit.edu/cmap/ and in GEO.
Cell culture and viability assays
CEM-c1, MOLT4, Raji, Ramos, REH, and NAMALWA cells were purchased
from ATCC (Manassas, VA). SU-DHL-1 and SUP-M2 were purchased from
DSMZ. All cells were maintained in RPMI-1640 media (Invitrogen, Carlsbad,
CA) supplemented with heat-inactivated 10% fetal bovine serum, 2 mM L-
glutamine, 13MEMnonessential amino acids, and 100 mM b-mercaptoetha-
nol. 2B4 cells infected by MIG-Myr-Akt and MIG vector control virus were
sorted based on GFP expression. Thymocytes and splenic cells were pre-
pared as described (Opferman et al., 2003) and cultured in 24-well dishes
in IMEM media (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum and
the same supplements as the above RPMI medium. MTT assay was carried
out according to the manufacturer’s instruction using an MTT kit (Promega).
Annexin V (BioVision, Mountain View, CA) and PI staining and FACS analysis
of apoptotic cells were performed as described (Opferman and Korsmeyer,
2003). The percentage of viable cells was determined by dividing the number
of Annexin V2/PI2 cell in the treated sample by the number of Annexin V2/
PI2 cells in the untreated sample for each time point or concentration. Error
bars represent the mean 6 standard deviation from duplicate or triplicates.
Mcl1 transgenic mice
A minigene containing the H2K promoter/enhancer and the Moloney MuLV
enhancer/poly(A) site driving the expression of mouse Mcl1 cDNA was339
A R T I C L Einjected into zygotes obtained from crosses between F1 (C57BL/6 3 C3H)
mice. Resulting progeny were tested by Southern blotting, and positive
mice were backcrossed to C57BL/6 mice. Four independent founder lines
were generated with different expression levels as tested by Western blot.
The transgenic mice were generated, housed, and bred in the Dana-Farber
Cancer Institute (DFCI) animal facility. All animal experiments were approved
by the Dana-Farber Cancer Institute IACUC.
Coimmunoprecipitation
2B4 cells expressing FLAG-MCL1 were treated with 100 nM dexamethasone
for 0–24 hr, then lysed in lysis buffer (50 mM Tris-Cl [pH 7.5], NaCl 150 mM,
1%CHAPS, proteinase inhibitors, 1 mMNaVO4, 2 mMNaF) at 4
C for 30 min
with rotation. After centrifugation, the supernatant was incubated with beads
conjugated with anti-FLAG M2 antibody (Sigma, St. Louis, MO) at 4C
overnight.
Real-time PCR
Real-time PCR was carried out as described using Sybr green (Wei et al.,
2004). For each gene, the value was adjusted by ribosomal protein L4.
Primers for real-time PCR are as follows: BIM: forward, AGACCACCCACG
AATGGTTA, reverse, GTGCTGGGTCTTGTTGGTTT; PUMA: forward, GACG
ACCTCAACGCACAGTA, reverse, CACCTAATTGGGCTCCATCT; human
ribosome protein L4: forward, CGTTTCTGCATTTGGACTGA, reverse, TCTT
GTGCATGGGAAGATTG.
RNAi
Lentiviral shRNA vectors for MCL1, BCL2, Bim, and Luciferase control were
kindly provided by Harvard/MIT Broad Institute RNA consortium. The target
sequences used for knockdown of the following genes are MCL1 mRNA
(NM_021960), nucleotides 3125–2145 (GCTGTGTTAAACCTCAGAGTT);
BCL2 mRNA (NM_000633), nucleotides 1019–1939 (TGGATGACTGAGTA
CCTGAAC); Bim mRNA (NM_009754), nucleotides 35–55 (GTTGGAGCTCT
GCGGTCCTTGC).
Microarray data
The data discussed in this publication have been deposited in NCBI’s Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) and are ac-
cessible through GEO series accession numbers GSE5258, GSE5820,
GSE5821, and GSE5822.
Supplemental data
The Supplemental Data include eight supplemental figures and one supple-
mental table and can be found with this article online at http://www.
cancercell.org/cgi/content/full/10/4/331/DC1/.
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